What is the share price of Nath Bio-Genes (I) Ltd (NATHBIOGEN) today?
The share price of NATHBIOGEN as on 31st July 2026 is ₹159.18. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The past returns of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share are- Past 1 week: -0.17%
- Past 1 month: -5.24%
- Past 3 months: -18.79%
- Past 6 months: 9.60%
- Past 1 year: -12.64%
- Past 3 years: -23.58%
- Past 5 years: -57.71%
What are the peers or stocks similar to Nath Bio-Genes (I) Ltd (NATHBIOGEN)?
The peers or stocks similar to Nath Bio-Genes (I) Ltd (NATHBIOGEN) include:What is the dividend yield % of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The current dividend yield of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is 1.26.What is the market cap of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is ₹302.51 Cr as of 31st July 2026.What is the 52 week high and low of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The 52-week high of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is ₹204 and the 52-week low is ₹126.15.What is the PE and PB ratio of Nath Bio-Genes (I) Ltd (NATHBIOGEN) stock?
The P/E (price-to-earnings) ratio of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is 7.26. The P/B (price-to-book) ratio is 0.47.Which sector does Nath Bio-Genes (I) Ltd (NATHBIOGEN) belong to?
Nath Bio-Genes (I) Ltd (NATHBIOGEN) belongs to the Consumer Staples sector & Agro Products sub-sector.How to buy Nath Bio-Genes (I) Ltd (NATHBIOGEN) shares?
You can directly buy Nath Bio-Genes (I) Ltd (NATHBIOGEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nath Bio-Genes (I) Ltd
NATHBIOGEN Share Price
NSE₹159.181.37% (-2.21)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NATHBIOGEN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NATHBIOGEN Performance & Key Metrics
NATHBIOGEN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 7.82 | 0.47 | 1.26% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.01 | 7.80 | 1.67% |
NATHBIOGEN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NATHBIOGEN Company Profile
Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds
GODREJAGRO
PE Ratio
22.65
22.65
1Y Return
34.28%
34.28%
Buy Reco %
100.00
100.00
PE Ratio
25.94
25.94
1Y Return
56.09%
56.09%
Buy Reco %
100.00
100.00
PE Ratio
18.01
18.01
1Y Return
239.37%
239.37%
Buy Reco %
0.00
0.00
BNAGROCHEM
PE Ratio
79.34
79.34
1Y Return
11.86%
11.86%
Buy Reco %
0.00
0.00
PE Ratio
21.08
21.08
1Y Return
21.41%
21.41%
Buy Reco %
0.00
0.00
NATHBIOGEN Sentiment Analysis
NATHBIOGEN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NATHBIOGEN Stock Summary · May 2026
The call conveyed solid top‑line momentum with disciplined, conservative execution. Consolidated revenue rose to INR 4,316 million, and management guided FY27 growth of 15–20% (using ~15% as a conservative planning assumption), while stressing that margin recovery will be gradual. Management emphasized an R&D‑led strategy — continued product rollouts across cotton, paddy, maize and vegetables, lifecycle management of flagship hybrids, and a robust FY27 pipeline — alongside measured international expansion from first Uzbekistan sales and a cautious target of modest overseas contribution over several years. They reported production stability after prior constraints and stronger volumes, but acknowledged tension as margins normalized versus the prior year and were impacted by higher finance costs and a higher tax rate, prompting deliberate inventory build and working‑capital use to support a scaled season. Capital allocation remains conservative and asset‑light, favoring rentals for processing and seasonal assets while expanding cold‑storage and distribution. Near term, management expects modest margin improvement (around 1–1.5 percentage points) as product adoption and operational levers take hold.
NATHBIOGEN Stock Growth Drivers
NATHBIOGEN Stock Growth Drivers
6Sustained multi-year financial momentum
The company delivered material top-line and earnings improvement in FY26 with consolidated revenue of INR
R&D‑led product leadership and commercial traction of flagship hybrids
A research‑first strategy underpins product competitiveness with decades of R&D, DSIR‑recognized innovation capability and a
NATHBIOGEN Stock Challenges
NATHBIOGEN Stock Challenges
5Plant Nutrition segment decline from export restrictions
The Plant Nutrition business contracted materially, with an 18% decline attributed primarily to export restrictions
Elevated working capital needs and higher finance costs
The company deliberately increased inventory to INR 4,446 million to support a scaled season, driving
NATHBIOGEN Forecast
NATHBIOGEN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NATHBIOGEN
NATHBIOGEN
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NATHBIOGEN Income Statement
NATHBIOGEN Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 44.40 | 244.01 | 32.27 | 37.35 | 56.37 | 287.53 | 47.85 | 70.38 | 55.23 | 331.50 | ||||||||||
Operating & Other expenses | 39.11 | 207.34 | 27.38 | 28.84 | 51.55 | 254.42 | 37.75 | 62.39 | 47.12 | 293.25 | ||||||||||
EBITDA | 5.29 | 36.67 | 4.89 | 8.51 | 4.82 | 33.11 | 10.10 | 7.99 | 8.11 | 38.25 | ||||||||||
| Depreciation/Amortization | 0.98 | 0.83 | 0.83 | 0.83 | 1.34 | 0.98 | 0.99 | 0.98 | 1.03 | 1.01 | ||||||||||
| PBIT | 4.31 | 35.84 | 4.06 | 7.68 | 3.48 | 32.13 | 9.11 | 7.01 | 7.08 | 37.24 | ||||||||||
| Interest & Other Items | 1.07 | 2.24 | 2.98 | 3.90 | 1.37 | 3.20 | 3.66 | 4.54 | 4.59 | 4.26 | ||||||||||
| PBT | 3.24 | 33.60 | 1.08 | 3.78 | 2.11 | 28.93 | 5.45 | 2.47 | 2.49 | 32.98 | ||||||||||
| Taxes & Other Items | 0.62 | 0.25 | -0.03 | 1.14 | 0.63 | 0.66 | 0.64 | 0.87 | 2.50 | 0.72 | ||||||||||
| Net Income | 2.62 | 33.35 | 1.11 | 2.64 | 1.48 | 28.27 | 4.81 | 1.60 | -0.01 | 32.26 | ||||||||||
| EPS | 1.87 | 17.49 | 0.53 | 1.33 | 0.42 | 14.88 | 2.53 | 0.89 | -0.79 | 16.98 |
NATHBIOGEN Company Updates
NATHBIOGEN Stock Peers
NATHBIOGEN Past Performance & Peer Comparison
NATHBIOGEN Past Performance & Peer Comparison
Comparing 3 stocks from
Consumer StaplesAgro Products
Compare valuation on Screener
Consumer StaplesAgro Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nath Bio-Genes (I) Ltd | 7.26 | 0.47 | 1.26% |
| Godrej Agrovet Ltd | 22.65 | 4.95 | 1.97% |
| Gujarat Ambuja Exports Ltd | 25.94 | 2.63 | 0.17% |
| Cian Agro Industries & Infrastructure Ltd | 18.01 | 1.99 | — |
NATHBIOGEN Stock Price Comparison
Compare NATHBIOGEN with any stock or ETFCompare NATHBIOGEN with any stock or ETF
NATHBIOGEN
NATHBIOGEN Holdings
NATHBIOGEN Shareholdings
NATHBIOGEN Promoter Holdings Trend
NATHBIOGEN Promoter Holdings Trend
NATHBIOGEN Institutional Holdings Trend
NATHBIOGEN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NATHBIOGEN Shareholding Pattern
NATHBIOGEN Shareholding Pattern
NATHBIOGEN Shareholding History
NATHBIOGEN Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NATHBIOGEN stock
smallcases containing NATHBIOGEN stock
Looks like this stock is not in any smallcase yet.
NATHBIOGEN Events
NATHBIOGEN Events
NATHBIOGEN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NATHBIOGEN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.26%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹12.56 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NATHBIOGEN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NATHBIOGEN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.26%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹12.56 every year
NATHBIOGEN Upcoming Dividends
NATHBIOGEN Upcoming Dividends
No upcoming dividends are available
NATHBIOGEN Past Dividends
NATHBIOGEN Past Dividends
Cash Dividend
Ex DateEx DateAug 14, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 14, 2025
Cash Dividend
Ex DateEx DateAug 9, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateJul 4, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 4, 2023
Cash Dividend
Ex DateEx DateJun 23, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 23, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
NATHBIOGEN Stock News & Opinions
NATHBIOGEN Stock News & Opinions
Articles & Videos
Earnings
Earnings
Nath Bio-Genes (India) consolidated net profit rises 14.07% in the June 2026 quarterNet profit of Nath Bio-Genes (India) rose 14.07% to Rs 32.26 crore in the quarter ended June 2026 as against Rs 28.28 crore during the previous quarter ended June 2025. Sales rose 15.76% to Rs 328.40 crore in the quarter ended June 2026 as against Rs 283.70 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales328.40283.70 16 OPM %10.7010.32 - PBDT32.7927.86 18 PBT31.7826.88 18 NP32.2628.28 14 Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to convene board meetingNath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 29 July 2026.
1 week agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to declare Quarterly Result & dividendNath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 4 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Nath Bio-Genes (India) consolidated net profit declines 39.62% in the December 2025 quarterNet profit of Nath Bio-Genes (India) declined 39.62% to Rs 1.60 crore in the quarter ended December 2025 as against Rs 2.65 crore during the previous quarter ended December 2024. Sales rose 78.90% to Rs 65.96 crore in the quarter ended December 2025 as against Rs 36.87 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.9636.87 79 OPM %5.4321.78 - PBDT0.764.62 -84 PBT-0.213.79 PL NP1.602.65 -40 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to conduct board meetingNath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Nath Bio-Genes (India) consolidated net profit rises 147.75% in the September 2025 quarterNet profit of Nath Bio-Genes (India) rose 147.75% to Rs 2.75 crore in the quarter ended September 2025 as against Rs 1.11 crore during the previous quarter ended September 2024. Sales rose 36.22% to Rs 43.85 crore in the quarter ended September 2025 as against Rs 32.19 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales43.8532.19 36 OPM %13.9114.94 - PBDT4.381.91 129 PBT3.391.09 211 NP2.751.11 148 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to declare Quarterly ResultsNath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Nath Bio-Genes (India) consolidated net profit rises 11.78% in the June 2025 quarterNet profit of Nath Bio-Genes (India) rose 11.78% to Rs 37.28 crore in the quarter ended June 2025 as against Rs 33.35 crore during the previous quarter ended June 2024. Sales rose 16.33% to Rs 283.70 crore in the quarter ended June 2025 as against Rs 243.88 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales283.70243.88 16 OPM %13.4914.98 - PBDT36.8634.43 7 PBT35.8833.60 7 NP37.2833.35 12 Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to announce Quarterly ResultNath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 11 July 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Corporate
Nath Bio-Genes (India) to convene AGMNath Bio-Genes (India) announced that the 32th Annual General Meeting(AGM) of the company will be held on 22 August 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant